<DOC>
	<DOCNO>NCT02957682</DOCNO>
	<brief_summary>The main purpose study evaluate effect mental state ( know `` neurocognitive function '' ) use Praluent .</brief_summary>
	<brief_title>Evaluating Effect Study Drug Praluent ( Alirocumab ) Neurocognitive Function When Compared Placebo</brief_title>
	<detailed_description />
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Men woman ≥ age 40 year ≤ age 85 year Patients heterozygous familial hypercholesterolemia ( heFH ) nonfamilial hypercholesterolemia ( nonFH ) patient high high cardiovascular risk Patients history coronary heart disease ( CHD ) adequate control hypercholesterolemia LDLC ≥70 mg/dL , patient LDLC ≥100 mg/dL maximallytolerated dose statin ( unless statinintolerant ) Patients must successfully complete Motor Screening Task Patients must willing able comply clinic visit study related procedure Patients must provide sign informed consent Patients know Alzheimer 's disease dementia , schizophrenia , bipolar disorder , severe depression , cognitive impairment , patient sleep disorder require daily pharmacological treatment Recent ( within 3 month prior screen visit ) myocardial infarction , unstable angina lead hospitalization , coronary artery bypass graft surgery , percutaneous coronary intervention , uncontrolled cardiac arrhythmia , carotid surgery stenting , stroke , transient ischemic attack , carotid revascularization , endovascular procedure surgical intervention peripheral vascular disease Certain laboratory finding obtain screen visit Any condition situation , include significant mental neurological disorder , investigator 's opinion , may confound study result , may interfere significantly patient 's participation study Pregnant breastfeed woman A positive human immunodeficiency virus ( HIV ) test The information list intend contain consideration relevant patient 's potential participation clinical trial inclusion/exclusion criterion list</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Hyperlipidemias</keyword>
	<keyword>Dyslipidemias</keyword>
	<keyword>Lipid Metabolism Disorders</keyword>
</DOC>